Phaseline

Companies › Orchid Pharma Europe

Orchid Pharma Europe: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 4; Hematology, Infectious disease; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cefepime
Bacterial penicillin-binding protein inhibitor
CEPE, ENMEPhase 2Complicated Urinary Tract Infection; Infection; Intestinal MicrobiomeMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03078010CefepimePhase 2Intestinal MicrobiomeHematologyFeb 2027
NCT07484633CefepimePhase 4InfectionInfectious diseaseAug 2028
NCT05826990CefepimePhase 2Complicated Urinary Tract InfectionInfectious diseaseMay 2029

Targets

CEPE (1) ENME (1)

Companies with the same targets

–

Companies built like this

S-INFINITY Pharmaceuticals Prothya Biosolutions Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.